|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:activeIngredient
|
gptkb:aripiprazole
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:associatedWith
|
gptkb:Abilify
gptkb:aripiprazole_lauroxil
|
|
gptkbp:ATCCode
|
gptkb:N05AX12
|
|
gptkbp:blackBoxWarning
|
suicidal thoughts and behaviors
increased mortality in elderly patients with dementia-related psychosis
|
|
gptkbp:brand
|
gptkb:aripiprazole
|
|
gptkbp:contraindication
|
known hypersensitivity to aripiprazole
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:form
|
extended-release injectable suspension
once-monthly injection
|
|
gptkbp:halfLife
|
29.9 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abilify Maintena
|
|
gptkbp:indication
|
schizophrenia
maintenance treatment of bipolar I disorder
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Otsuka_Pharmaceutical
gptkb:Lundbeck
|
|
gptkbp:mechanismOfAction
|
antagonist at serotonin 5-HT2A receptors
partial agonist at dopamine D2 receptors
partial agonist at serotonin 5-HT1A receptors
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
anxiety
headache
weight gain
insomnia
akathisia
|
|
gptkbp:bfsParent
|
gptkb:Lundbeck
gptkb:H._Lundbeck_A/S
gptkb:H_Lundbeck
|
|
gptkbp:bfsLayer
|
7
|